SCHEMBL1847293

SCHEMBL1847293

CNc1cc(-c2cn(Cc3ccc(OC)cc3)nc2-c2cccc([N+](=O)[O-])c2)ccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MAPK8 P45983 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
PDE4D Q08499 2/20 0.40
PDE4B Q07343 2/20 0.40
RAF1 P04049 1/20 0.40
BRAF P15056 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850730 0.92 MAPK8 (0.46) KMT2AMAPK8CYP3A4CYP2D6MAPK9
SCHEMBL1851520 0.91 MAPK8 (0.45) KMT2AMAPK8CYP3A4CYP2D6MAPK9
SCHEMBL1846522 0.90 KMT2A (0.46) KMT2AMAPK8CYP3A4CYP2D6MAPK9
SCHEMBL1847753 0.90 MAPK8 (0.47) KMT2AMAPK8CYP3A4CYP2D6MAPK9
SCHEMBL1974339 0.88 MAPK8 (0.46) KMT2AMAPK8CYP3A4CYP2D6MAPK9
SCHEMBL1848411 0.87 PDE4D (0.48) KMT2ACYP3A4CYP2D6MAPTSMN1; SMN2
SCHEMBL1852300 0.85 MAPK8 (0.42) KMT2AMAPK8CYP3A4CYP2D6MAPK9
SCHEMBL1847735 0.81 KMT2A (0.48) KMT2ACYP3A4CYP2D6MAPTSMN1; SMN2
SCHEMBL1847064 0.81 MAPT (0.44) KMT2AMAPTSMN1; SMN2MEN1PDE4D
SCHEMBL1847299 0.80 KMT2A (0.43) KMT2AMAPK9MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-01-02 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
EP-2324008-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-25 EP disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 KMT2A 1195/4885MAPK8 238/4885CYP3A4 1358/4885
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 KMT2A 1195/4885MAPK8 238/4885CYP3A4 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.